Conmed (CNMD) Tops, Profit Soars

Conmed Corporation (CNMD) reported second-quarter fiscal 2010 adjusted earnings per share of 32 cents, comfortably beating the Zacks Consensus Estimate of 26 cents while surpassing year-ago earnings of 17 cents. Restructuring expenses include costs of transferring product lines to the company’s new manufacturing facility in Chihuahua, Mexico.

Net income sailed to $7.3 million (or 25 cents a share), representing an astounding five-fold year-over-year growth. Results were boosted by forecast-beating top-line growth and cost synergies from the company’s ongoing restructuring initiatives.


Revenues soared 10% year over year to $181.1 million, well ahead of the Zacks Consensus Estimate of $177 million. Growth was fueled by healthy contributions from major business segments such as Arthroscopy (37% of sales), Powered Surgical (20%) and Electrosurgery (14%).

Arthroscopy revenues increased 21.6% year over year to $61.6 million. Powered Surgical Instruments sales increased 6.6% year over year to $33.5 million while revenues from Electrosurgery rose 5.7% year over year to $22.7 million.

Total Single-use and reposable revenues increased 7% year over year to $129.2 million, while consolidated revenues from capital equipment increased 21.2% to $35.4 million.


Gross margin improved to 51.7% from 46.9% a year ago as the company spent less on the Mexican manufacturing facility. Higher gross margin led to an increase in operating margin, which increased to 8.2% from 3% a year ago.

Cash flow & Share Repurchases

Conmed generated $18.5 million (roughly 10% of sales) in cash flows from operation in the quarter, which was utilized to buy back shares and repay debt. The company repurchased roughly 475,000 shares during the quarter for $9.5 million and also bought back and retired convertible notes worth $3 million.


Conmed has maintained its revenues and adjusted earnings guidance for fiscal 2010. The company continues to expect total revenues in the range of $715 million to $725 million and adjusted EPS between $1.20 and $1.30.

For the third quarter, revenues are projected between $174 million and $179 million with adjusted EPS in the range of 25 – 30 cents. The company believes the seasonality factor would trim third quarter revenues on a sequential basis.

Conmed is a major medical products manufacturer specializing in surgical instruments and devices. The company operates in a highly-competitive orthopedic surgery markets against much larger, technically-competent companies, such as Johnson & Johnson (JNJ), Smith & Nephew (SNN), Stryker Corporation (SYK).

CONMED CORP (CNMD): Free Stock Analysis Report

About Zacks Investment Research 1766 Articles

Zacks Investment Research is one of the most highly regarded firms in the investment industry. In 1978 Zacks originated the concept of utilizing earnings estimates revisions to make profitable investment decisions. Zacks offers multiple investment products and services to help investors achieve superior returns.


Be the first to comment

Leave a Reply

Your email address will not be published.